VIDEO: VOYAGER, Atherosclerotic Disease, and More
Marc P. Bonaca, MD, talks with DocWire News about his work with the VOYAGER-PAD study, rivaroxaban, and other interesting topics.
Marc P. Bonaca, MD, talks with DocWire News about his work with the VOYAGER-PAD study, rivaroxaban, and other interesting topics.
None of the popular videos included content from healthcare providers.
Most patients switching from modafinils to solriamfetol preferred it, citing better effects; others reverted due to side effects.
The prospective case series demonstrates the efficacy of the combination in second- and later-line treatment.
Targeted therapies directed toward tumor genotype should be considered in addition to standard-of-care regimens.
This was an unexpected finding because mature TLS are typically rare in poorly immunogenic HPV-negative HNSCC.
The findings reaffirm concurrent chemoradiotherapy as a cornerstone of treatment.
Tumor mutations were even detected in early-stage disease.
Researchers identified the pathologic and clinical characteristics of patients who experience disease relapse.
Patient-derived cells have the potential to enhance drug screening tools and improve patient outcomes.
Study finds early lebrikizumab response in AD linked to lower inflammation—may guide personalized treatment plans.